MA43347A - Compositions et méthodes permettant d'inhiber l'expression du gène de lpa - Google Patents

Compositions et méthodes permettant d'inhiber l'expression du gène de lpa

Info

Publication number
MA43347A
MA43347A MA43347A MA43347A MA43347A MA 43347 A MA43347 A MA 43347A MA 43347 A MA43347 A MA 43347A MA 43347 A MA43347 A MA 43347A MA 43347 A MA43347 A MA 43347A
Authority
MA
Morocco
Prior art keywords
agents
arni
lpa
compositions
methods
Prior art date
Application number
MA43347A
Other languages
English (en)
Other versions
MA43347B1 (fr
Inventor
Aaron Almeida
Lauren J Almeida
Steven Kanner
David L Lewis
Zhen Li
Tao Pei
David B Rozema
Vladimir S Trubetskoy
Darren H Wakefield
Original Assignee
Arrowhead Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arrowhead Pharmaceuticals Inc filed Critical Arrowhead Pharmaceuticals Inc
Publication of MA43347A publication Critical patent/MA43347A/fr
Publication of MA43347B1 publication Critical patent/MA43347B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3517—Marker; Tag

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Des agents d'interférence d'arn (arni) et des conjugués d'agents d'arni pour inhiber l'expression du gène de la lpa (apo (a)) sont décrits. Des compositions pharmaceutiques comprenant un ou plusieurs agents arni lpa, éventuellement avec un ou plusieurs agents thérapeutiques supplémentaires, sont également décrites. La délivrance des agents arni lpa décrits aux cellules hépatiques in vivo permet d'inhiber l'expression du gène lpa et le traitement des maladies cardiovasculaires et cardiovasculaires.
MA43347A 2015-10-01 2017-04-06 Compositions et méthodes permettant d'inhiber l'expression du gène de lpa MA43347B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562235816P 2015-10-01 2015-10-01
US201662346304P 2016-06-06 2016-06-06
US201662383221P 2016-09-02 2016-09-02
PCT/US2016/054729 WO2017059223A2 (fr) 2015-10-01 2016-09-30 Compositions et méthodes permettant d'inhiber l'expression du gène de lpa

Publications (2)

Publication Number Publication Date
MA43347A true MA43347A (fr) 2018-08-08
MA43347B1 MA43347B1 (fr) 2021-11-30

Family

ID=58424351

Family Applications (1)

Application Number Title Priority Date Filing Date
MA43347A MA43347B1 (fr) 2015-10-01 2017-04-06 Compositions et méthodes permettant d'inhiber l'expression du gène de lpa

Country Status (37)

Country Link
US (3) US9932586B2 (fr)
EP (2) EP4029941A1 (fr)
JP (4) JP6991966B2 (fr)
KR (1) KR20180052703A (fr)
CN (1) CN108368506A (fr)
AU (2) AU2016331084B2 (fr)
BR (1) BR112018006489A2 (fr)
CA (1) CA3000397A1 (fr)
CL (1) CL2018000803A1 (fr)
CO (1) CO2018003678A2 (fr)
CR (1) CR20180231A (fr)
CY (1) CY1125263T1 (fr)
DK (1) DK3356529T3 (fr)
EA (1) EA038478B1 (fr)
ES (1) ES2896298T3 (fr)
HK (1) HK1259063A1 (fr)
HR (1) HRP20211410T1 (fr)
HU (1) HUE055942T2 (fr)
IL (3) IL300438A (fr)
JO (2) JOP20210043A1 (fr)
LT (1) LT3356529T (fr)
MA (1) MA43347B1 (fr)
MX (2) MX2018003833A (fr)
MY (1) MY195796A (fr)
PE (1) PE20181139A1 (fr)
PH (1) PH12018500713A1 (fr)
PL (1) PL3356529T3 (fr)
PT (1) PT3356529T (fr)
RS (1) RS62523B1 (fr)
SG (1) SG10202008530TA (fr)
SI (1) SI3356529T1 (fr)
TN (1) TN2018000094A1 (fr)
TW (2) TWI784934B (fr)
UA (1) UA121998C2 (fr)
UY (1) UY36926A (fr)
WO (1) WO2017059223A2 (fr)
ZA (1) ZA202106265B (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7718133B2 (en) 2003-10-09 2010-05-18 3M Innovative Properties Company Multilayer processing devices and methods
CN113797348A (zh) * 2016-03-07 2021-12-17 箭头药业股份有限公司 用于治疗性化合物的靶向配体
JP6989521B2 (ja) 2016-09-02 2022-01-05 アローヘッド ファーマシューティカルズ インコーポレイテッド 標的化リガンド
WO2018185241A1 (fr) 2017-04-05 2018-10-11 Silence Therapeutics Gmbh Produits et compositions
WO2019010274A1 (fr) * 2017-07-06 2019-01-10 Arrowhead Pharmaceuticals, Inc. Agents arni d'inhibition d'expression de gène alpha-enac et méthodes d'utilisation
TN2020000039A1 (en) * 2017-09-11 2021-10-04 Arrowhead Pharmaceuticals Inc Rnai agents and compositions for inhibiting expression of apolipoprotein c-iii (apoc3)
SG11201912188RA (en) * 2017-09-14 2020-01-30 Arrowhead Pharmaceuticals Inc Rnai agents and compositions for inhibiting expression of angiopoietin-like 3 (angptl3), and methods of use
AU2018352379A1 (en) * 2017-10-17 2020-06-04 Arrowhead Pharmaceuticals, Inc. RNAi agents and compositions for inhibiting expression of Asialoglycoprotein receptor 1
EP3483270A1 (fr) * 2017-11-13 2019-05-15 Silence Therapeutics GmbH Produits et compositions
EP3710586B1 (fr) * 2017-11-13 2022-11-23 Silence Therapeutics GmbH Produits et compositions
AU2019342117A1 (en) * 2018-09-19 2021-03-04 Arrowhead Pharmaceuticals, Inc. RNAi agents for inhibiting expression of 17beta-HSD type 13- (HSD17B13), compositions thereof, and methods of use
BR112021009213A2 (pt) * 2018-11-13 2021-08-10 Silence Therapeutics Gmbh ácidos nucleicos para inibição da expressão de lpa em uma célula
WO2021119034A1 (fr) 2019-12-09 2021-06-17 Amgen Inc. Constructions d'arni et procédés d'inhibition de l'expression de lpa
AU2021320550A1 (en) * 2020-08-05 2023-02-16 Dicerna Pharmaceuticals, Inc. Compositions and methods for inhibiting
WO2022079221A1 (fr) * 2020-10-16 2022-04-21 Sanofi Compositions d'arn et méthodes d'inhibition de lipoprotéine (a)
TW202233837A (zh) 2020-11-05 2022-09-01 美商安進公司 用靶向ＬＰＡ的ＲＮＡｉ構建體治療動脈粥樣硬化性心血管疾病之方法
WO2022121959A1 (fr) * 2020-12-09 2022-06-16 纳肽得有限公司 Molécule d'arnsi et son application dans le traitement de maladies des artères coronaires
JP2024500035A (ja) 2020-12-23 2024-01-04 アルゴノート アールエヌエー リミテッド 心血管疾患の治療
CN117836307A (zh) 2021-06-18 2024-04-05 弘景生物科技有限公司 功能化的n-乙酰基半乳糖胺核苷
EP4396193A1 (fr) 2021-08-30 2024-07-10 Hongene Biotech Corporation Analogues de n-acétylgalactosamine fonctionnalisés
WO2023041508A2 (fr) 2021-09-14 2023-03-23 Argonaute RNA Limited Traitement d'une maladie cardiovasculaire
CA3232191A1 (fr) * 2021-09-18 2023-03-23 Chong Li Inhibiteur de lpa et son utilisation
WO2023114746A1 (fr) 2021-12-15 2023-06-22 Hongene Biotech Corporation Analogues de n-acétylgalactosamine fonctionnalisés
CN114703184B (zh) * 2022-03-11 2024-06-18 厦门甘宝利生物医药有限公司 Lpa抑制剂及其用途
WO2024032681A1 (fr) * 2022-08-11 2024-02-15 益杰立科(上海)生物科技有限公司 Procédé pour cible d'édition d'épitope et utilisation
CN115851723B (zh) * 2022-10-24 2023-10-03 厦门甘宝利生物医药有限公司 一种抑制lpa基因表达的rna抑制剂及其应用
WO2024118503A1 (fr) 2022-11-28 2024-06-06 Hongene Biotech Corporation Analogues de n-acétylgalactosamine fonctionnalisés
WO2024151937A1 (fr) * 2023-01-13 2024-07-18 Eli Lilly And Company Compositions pharmaceutiques contenant des oligonucléotides thérapeutiques et schémas posologiques les utilisant
WO2024210530A1 (fr) * 2023-04-03 2024-10-10 Olix Pharmaceuticals, Inc. Agents arni ciblant le gène lpa et leur utilisation

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9201440A (nl) 1992-08-11 1994-03-01 Univ Leiden Triantennaire clusterglycosiden, hun bereiding en toepassing.
US5599706A (en) 1994-09-23 1997-02-04 Stinchcomb; Dan T. Ribozymes targeted to apo(a) mRNA
EP1159441B8 (fr) 1999-03-10 2008-10-29 Marie Curie Cancer Care Administration de substances a des cellules
CZ308053B6 (cs) * 2000-12-01 2019-11-27 Max Planck Gesellschaft Izolovaná molekula dvouřetězcové RNA, způsob její výroby a její použití
US7259150B2 (en) 2001-08-07 2007-08-21 Isis Pharmaceuticals, Inc. Modulation of apolipoprotein (a) expression
US7227014B2 (en) 2001-08-07 2007-06-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein (a) expression
ATE471722T1 (de) 2003-03-12 2010-07-15 Univ Arizona State Verfahren zur regulierung von angiogenese mit apelin-zusammensetzungen
CA2559955C (fr) 2004-03-15 2016-02-16 City Of Hope Procedes et compositions pour l'inhibition specifique de l'expression genetique par l'arn double brin
JP5274461B2 (ja) * 2006-08-18 2013-08-28 アローヘッド リサーチ コーポレイション ポリヌクレオチドのインビボ送達のためのポリ結合体
US8513207B2 (en) 2008-12-18 2013-08-20 Dicerna Pharmaceuticals, Inc. Extended dicer substrate agents and methods for the specific inhibition of gene expression
WO2010093788A2 (fr) 2009-02-11 2010-08-19 Dicerna Pharmaceuticals, Inc. Molécules d'arn interférence substrats de dicer multiplexes ayant des séquences de jonction
PT2539451E (pt) 2010-02-24 2016-03-28 Arrowhead Res Corp Composições para entrega de arnsi dirigida ao alvo
WO2011141703A1 (fr) * 2010-05-12 2011-11-17 Protiva Biotherapeutics Inc. Compositions et procédés pour réduire au silence l'apolipoprotéine b
EP3192800A1 (fr) 2010-12-17 2017-07-19 Arrowhead Pharmaceuticals, Inc. Fraction de ciblage complexe de galactose-modulateur pharmacocinétique pour arnsi
US8501930B2 (en) * 2010-12-17 2013-08-06 Arrowhead Madison Inc. Peptide-based in vivo siRNA delivery system
KR20130136494A (ko) 2010-12-29 2013-12-12 애로우헤드 리서치 코오포레이션 효소 민감성 결합을 갖는 Ｉｎ Ｖｉｖｏ 폴리뉴클레오티드 전달 컨쥬게이트
MX2014001971A (es) 2011-08-26 2014-03-31 Arrowhead Res Corp Polimeros de poli(vinilester) para suministro de acido nucleico in vivo.
PE20142362A1 (es) * 2011-11-18 2015-01-30 Alnylam Pharmaceuticals Inc Agentes de iarn, composiciones y metodos de uso de los mismos para tratar enfermedades asociadas con transtiretina (ttr)
BR112014004528A2 (pt) 2012-04-18 2019-09-24 Arrowhead Res Corp polímeros de poli(acrilato) para entrega de ácido nucleico in vivo
WO2013177468A2 (fr) 2012-05-24 2013-11-28 Isis Pharmaceuticals, Inc. Procédés et compositions de modulation de l'expression de l'apolipoprotéine(a)
RU2686080C2 (ru) 2013-05-01 2019-04-24 Ионис Фармасьютикалз, Инк. Композиции и способы
US20160272970A1 (en) 2015-03-17 2016-09-22 Arrowhead Madison Inc. RNA Interference Agents
CN114601845A (zh) 2015-05-29 2022-06-10 箭头药业股份有限公司 抑制Hif2α基因表达的组合物及方法
US10208307B2 (en) * 2015-07-31 2019-02-19 Alnylam Pharmaceuticals, Inc. Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases
CN113797348A (zh) 2016-03-07 2021-12-17 箭头药业股份有限公司 用于治疗性化合物的靶向配体

Also Published As

Publication number Publication date
EP3356529B1 (fr) 2021-08-25
TW201726918A (zh) 2017-08-01
EA201890864A1 (ru) 2018-09-28
TN2018000094A1 (en) 2019-07-08
JOP20160211B1 (ar) 2021-08-17
CR20180231A (es) 2018-05-31
TW202332769A (zh) 2023-08-16
US20170096665A1 (en) 2017-04-06
EP3356529A4 (fr) 2019-09-04
LT3356529T (lt) 2021-12-27
PH12018500713A1 (en) 2018-10-15
MX2018003833A (es) 2018-06-18
NZ741086A (en) 2023-11-24
BR112018006489A2 (pt) 2018-10-09
PL3356529T3 (pl) 2021-12-20
ZA202106265B (en) 2023-08-30
DK3356529T3 (da) 2021-11-08
HK1259063A1 (zh) 2019-11-22
JP2022113835A (ja) 2022-08-04
HRP20211410T1 (hr) 2021-12-24
IL290566B2 (en) 2023-07-01
IL290566B1 (en) 2023-03-01
AU2022283623A1 (en) 2023-02-02
AU2016331084A1 (en) 2018-04-19
EA038478B1 (ru) 2021-09-03
CL2018000803A1 (es) 2018-08-31
HUE055942T2 (hu) 2022-01-28
CY1125263T1 (el) 2023-03-24
SG10202008530TA (en) 2020-10-29
WO2017059223A2 (fr) 2017-04-06
WO2017059223A3 (fr) 2017-05-11
JP6991966B2 (ja) 2022-02-03
US20200263179A1 (en) 2020-08-20
TWI784934B (zh) 2022-12-01
JP2018529732A (ja) 2018-10-11
MX2022013010A (es) 2022-11-09
CA3000397A1 (fr) 2017-04-06
UA121998C2 (uk) 2020-08-25
KR20180052703A (ko) 2018-05-18
IL258333B (en) 2022-03-01
CO2018003678A2 (es) 2018-11-30
JP7116212B2 (ja) 2022-08-09
MY195796A (en) 2023-02-21
IL258333A (en) 2018-05-31
SI3356529T1 (sl) 2022-01-31
JP2021087459A (ja) 2021-06-10
PE20181139A1 (es) 2018-07-17
MA43347B1 (fr) 2021-11-30
RS62523B1 (sr) 2021-11-30
US20180195070A1 (en) 2018-07-12
EP4029941A1 (fr) 2022-07-20
US9932586B2 (en) 2018-04-03
PT3356529T (pt) 2021-11-04
IL300438A (en) 2023-04-01
CN108368506A (zh) 2018-08-03
US10662427B2 (en) 2020-05-26
EP3356529A2 (fr) 2018-08-08
AU2016331084B2 (en) 2022-09-08
ES2896298T3 (es) 2022-02-24
IL290566A (en) 2022-04-01
UY36926A (es) 2017-04-28
TWI836693B (zh) 2024-03-21
WO2017059223A9 (fr) 2017-08-17
JP2024009262A (ja) 2024-01-19
JOP20210043A1 (ar) 2017-06-16
JP7442574B2 (ja) 2024-03-04

Similar Documents

Publication Publication Date Title
MA43347A (fr) Compositions et méthodes permettant d'inhiber l'expression du gène de lpa
MY202025A (en) Rnai agents and compositions for inhibiting expression of apolipoprotein c-iii (apoc3)
JOP20200050A1 (ar) عوامل RNAi وتركيبات لتثبيط التعبير عن شبيه آنجيوبويتين 3 (ANGPTL3)، وطرق استخدام
EP4272731A3 (fr) Compositions pour l'administration d'agents thérapeutiques et leurs méthodes d'utilisation et leurs procédés de préparation
WO2018140920A8 (fr) Compositions et méthodes d'inhibition de l'expression génique du facteur xii
PH12016500575A1 (en) Inhibitors of bruton`s tyrosine kinase
PH12015500940A1 (en) Bruton`s tyrosine kinase inhibitors
TN2015000174A1 (en) Pyrrolopyrimidine compounds as kinase inhibitors
PH12014501815A1 (en) Purinone compounds as kinase inhibitors
MX2015001122A (es) Combinaciones farmaceuticas de un inhibidor de cdk4/6 y un inhibidor de b-raf.
MA40791A (fr) Ciblage lysosomal d'enzymes et utilisations associées
EA201692318A1 (ru) Композиции и способы для ингибирования экспрессии гена альфа-1-антитрипсина
EA201792103A1 (ru) Композиции и способы для ингибирования экспрессии генов hif2альфа
GB201213484D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
EA201791225A1 (ru) Композиции и способы применения солабегрона с модифицированным высвобождением при симптомах нижних мочевых путей
WO2016030899A8 (fr) Méthodes de traitement de la sclérose latérale amyotrophique
TW201613926A (en) Inhibitors of bruton's tyrosine kinase
MX2022002340A (es) Inhibidores conjugados de la respuesta al daño de adn.
CR20200117A (es) Agentes de iarn y composiciones para inhibir la expresión de la angiopoyetina tipo 3 (angptl3) y métodos de uso
EA202090234A1 (ru) СРЕДСТВА РНКи ДЛЯ ИНГИБИРОВАНИЯ ЭКСПРЕССИИ АЛЬФА-ENaC И СПОСОБЫ ПРИМЕНЕНИЯ
Ballis NAPSA: NAPSA charity cup campaign reaches new heights
UA110910C2 (uk) Карбоксамідні похідні піразолу як інгібітори тирозинкінази брутона, фармацевтична композиція на їх основі та спосіб лікування захворювань (варіанти)